Paul Ceplenski, MD
Urology · New Britain, CTNPI 1275564205
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,740 of the $4,354 with a category attached, or 85.9%. 32 manufacturers reported payments, led by Astellas Pharma US Inc at 27.3% of the total.
Across 203 payments — averaging $21.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$1K
- Bayer$478
- Pfizer$412
- Sumitomo Pharma America, Inc.$320
- Johnson & Johnson$265
- Urovant Sciences Inc$170
- plus $2K from 26 others
What the payments were for
- Food & beverage$3,74086%
- Education$61414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 54 | $1,189 |
| Bayer | 21 | $478 |
| Pfizer | 23 | $412 |
| Sumitomo Pharma America, Inc. | 14 | $320 |
| Johnson & Johnson | 14 | $265 |
| Urovant Sciences Inc | 8 | $170 |
| Rochester Medical Corporation | 4 | $155 |
| Myriad Genetic Laboratories, Inc. | 7 | $137 |
| Urogen Pharma, Inc. | 3 | $101 |
| Endo Pharmaceuticals Inc. | 5 | $100 |
| Tolmar Pharmaceuticals, Inc. | 5 | $92 |
| Merck | 5 | $92 |
| Myovant Sciences Inc. | 4 | $92 |
| Amgen | 4 | $80 |
| Dentsply IH Inc. | 2 | $66 |
| Hollister Incorporated | 4 | $65 |
| C. R. Bard, Inc. & Subsidiaries | 2 | $64 |
| Progenics Pharmaceuticals, Inc. | 2 | $54 |
| AbbVie | 3 | $52 |
| Telix Pharmaceuticals | 3 | $51 |
| Ferring Pharmaceuticals Inc. | 2 | $49 |
| Aytu Biopharma, Inc. | 3 | $48 |
| BD | 1 | $38 |
| Siemens Medical Solutions USA, Inc. | 2 | $35 |
| Novartis | 1 | $29 |
| Acerus Pharmaceuticals Corporation | 1 | $23 |
| Accord Healthcare, Inc. | 1 | $21 |
| Therapeuticsmd, Inc. | 1 | $19 |
| Endo USA, Inc. | 1 | $18 |
| AMAG Pharmaceuticals, Inc. | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Metuchen Pharmaceuticals | 1 | $11 |
How this compares
$4,354 in reported general payments places this provider in the 65th percentile of 156 urology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 76 | $1,074,325 |
| ErleadaApalutamide | 38 | $569,317 |
| GemtesaVibegron | 282 | $306,294 |
| MyrbetriqMirabegron | 128 | $105,236 |
| Tamsulosin Hcl | 2,344 | $37,018 |
| Silodosin | 362 | $28,064 |
| Mirabegron ErMirabegron | 17 | $10,611 |
| Finasteride | 735 | $7,751 |
| Tolterodine Tartrate ErTolterodine Tartrate | 108 | $7,653 |
| Methenamine Hippurate | 126 | $6,841 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 231 | $5,997 |
| Potassium Citrate ErPotassium Citrate | 42 | $4,451 |
| Testosterone | 28 | $4,111 |
| Oxybutynin Chloride ErOxybutynin Chloride | 180 | $3,397 |
| Tadalafil | 15 | $2,470 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $1,189 | $1,179,561204 claims |
| Johnson & JohnsonErleada | $265 | $569,31738 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $320 | $306,294282 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 156 urology providers in Connecticut.
Other urology in New Britain
- Joshua SteinNew Britain$30K
- Corlis Archer GoodeNew Britain$3K
- Daniel KellnerNew Haven$122K
- Gerard PregenzerEnfield$92K
- Mary SoysterTorrington$58K
- Preston SprenkleNew Haven$57K
- Grace BiggsDerby$52K
- Stanton HonigNew Haven$40K
- Steven ShichmanHartford$28K
- Christine LiawBridgeport$27K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.